Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects

A. Kliewer\textsuperscript{1}, F. Schmiedel\textsuperscript{1}, S. Sianati\textsuperscript{2}, A. Bailey\textsuperscript{3}, J.T. Bateman\textsuperscript{4}, E.S. Levitt\textsuperscript{4}, J.T. Williams\textsuperscript{5}, M.J. Christie\textsuperscript{2} & S. Schulz\textsuperscript{1}

Opioid analgesics are powerful pain relievers; however, over time, pain control diminishes as analgesic tolerance develops. The molecular mechanisms initiating tolerance have remained unresolved to date. We have previously shown that desensitization of the μ-opioid receptor and interaction with β-arrestins is controlled by carboxyl-terminal phosphorylation. Here we created knockin mice with a series of serine- and threonine-to-alanine mutations that render the receptor increasingly unable to recruit β-arrestins. Desensitization is inhibited in locus coeruleus neurons of mutant mice. Opioid-induced analgesia is strongly enhanced and analgesic tolerance is greatly diminished. Surprisingly, respiratory depression, constipation, and opioid withdrawal signs are unchanged or exacerbated, indicating that β-arrestin recruitment does not contribute to the severity of opioid side effects and, hence, predicting that G-protein-biased μ-agonists are still likely to elicit severe adverse effects. In conclusion, our findings identify carboxyl-terminal multisite phosphorylation as key step that drives acute μ-opioid receptor desensitization and long-term tolerance.
Opioid analgesics continue to be the most effective drugs for managing severe pain, but their clinical utility is limited by life-threatening respiratory depression, and the development of analgesic tolerance and addiction after repeated administration. These adverse effects underline the alarming increase in morbidity and mortality associated with the recent escalation of abuse of prescription and potent illicit opioids. Potential mechanisms of tolerance development that drive dose escalation include agonist-induced desensitization of the μ-opioid receptor (MOP), driven by agonist-induced phosphorylation of S/T residues in the receptor carboxyl-terminal with subsequent recruitment of regulatory proteins including β-arrestins. Agonist-induced desensitization and internalization of MOP occurs within seconds to minutes, whereas analgesic tolerance develops over days to weeks, because during chronic opioid exposure a number of adaptive biochemical processes occur, including upregulation of adenylyl cyclases, that may also critically support opioid tolerance.1-5. However, the individual contributions of MOP desensitization and cellular adaptation, and the molecular mechanisms initiating analgesic tolerance remain unresolved.

MOP desensitization is thought to be initiated by the phosphorylation of S and T residues on the cytoplasmic loops and carboxyl-terminal tail following receptor activation. The carboxyl-terminal tail of MOP contains 11S/T sites. Two specific cassettes of MOP residues that undergo rapid agonist-induced phosphorylation, 354TSST357 and 370TREHPSTANT379, have been identified in cultured cells in vitro and in mouse brain in vivo using phosphosite-specific antibodies and quantitative mass spectrometry.6-9. Within the 354TSST357 cassette, S356 and T357 are phosphorylated in an agonist-dependent manner.4,9,10. However, complete alanine mutation of the TSST motif does not affect desensitization or internalization of MOP in HEK293 cells.5,9. Within the 370TREHPSTANT379 cassette, S375 in the middle of this sequence is the primary site of phosphorylation in vitro in HEK293 and AtT20 cells6,8, as well as in mouse brain in vivo.11. Agonists having low-efficiency for phosphorylation and β-arrestin recruitment such as morphine induce a selective phosphorylation at S375 that does not facilitate receptor internalization either in HEK293 cells6,8 or mouse brain11. After overexpression of GRK2 or GRK3 in cultured cells, morphine is able to promote multisite phosphorylation and internalization of MOP.12. By contrast, high-efficiency opioids such as DAMGO and fentanyl not only induce phosphorylation of S375 but also drive higher-order phosphorylation on the flanking residues T370, T376 and T379 in a hierarchical phosphorylation cascade that specifically requires G-protein-coupled receptor kinases (GRK) 2 and 3 in HEK293 cells12 and in mouse brain.11. This multisite phosphorylation in turn promotes both β-arrestin recruitment and robust receptor internalization in HEK293 cells.6,13. In fact, mutation studies have revealed that mutations comprising all four genotypes. In all experiments, outward currents peak and decline during the 10 min application period of a saturating concentration of the endogenous opioid peptide [Met5]enkephalin (ME) (Fig. 1c). The decline from the peak values varies with genotype. In slices from WT and S375A animals, currents decrease to 50-60% of peak values, whereas the decline is much smaller in slices from 10S/T-A and 11S/T-A animals (Fig. 1c, d). Following washout of ME, effects of 1 µM ME are reduced by ~50% in slices from WT and S375A animals, but remain almost unchanged in 10S/T-A and 11S/T-A animals (Fig. 1c, d) compared to controls. Application of ME (1 µM) at various times following washout of the saturating ME concentration establishes that recovery from the smaller desensitization in slices from 10S/T-A and 11S/T-A animals is rapid, occurring within 5–10 min (Fig. 1c, d). Thus, mutation of S/T sites on the carboxyl-terminus of MOP results in a profound reduction, but not elimination, of two measures of acute desensitization. The small residual desensitization in 10S/T-A and 11S/T-A neurons resembles the heterologous desensitization that has been reported between MOP and the alpha-2-adrenoceptor upon activation of the same potassium conductance.15. The observation that 11S/T-A and 10S/T-A mice have very similar phenotypes indicates that phosphorylation of T394 is not involved in rapid MOP desensitization.

**Enhanced opioid analgesia.** We then compared acute antinociceptive responses in S375A, 10S/T-A, 11S/T-A and WT mice in the hot-plate test. Basal pain responses do not differ between genotypes (Supplementary Fig. 4). Mice were given repeated cumulative doses of fentanyl or morphine to generate dose-response curves. Homozygous 10S/T-A and 11S/T-A animals show greater antinociception than their WT littermates (Fig. 2a). Such robust responses to fentanyl are absent in WT littermates. Interestingly, heterozygous 10S/T-A mice also exhibit significantly greater antinociception than WT mice, suggesting a

**Results**

**Creation of knock-in mouse lines.** To assess the contribution of phosphorylation to MOP signalling in vivo, we created novel knock-in mice with 11S/T-A mutations (Oprm1tm3.1Shlz, MGI:6117673, 11S/T-A). Ten of the 11S/T sites are encoded by exon 4. T394 is encoded by exon 5. Exons 4 and 5 are separated by >19 kb of intronic sequence; therefore, simultaneous mutagenesis of all 11S/T sites required knock-in of a fusion of the two exons. To produce a graded deficit in S/T phosphorylation and β-arrestin recruitment, we created another knock-in mouse line (Oprm1tm2.1Shlz, MGI:6117668, 10S/T-A) with mutations in all 10 exon 4-encoded carboxyl-terminal S/T-residues except T394, and a third line with a single mutation of S375 to A (S375A) (Oprm1tm3.1Shlz, MGI:5000465)14 (Fig. 1a). All three transgenic lines are viable without gross phenotypic abnormalities. Autoradiographic binding assays revealed that MOP density in brains from all three knock-in lines is not significantly different from that observed in brains from C57BL/6 wild-type animals (WT) (Fig. 1b, Supplementary Fig. 1). Furthermore no differences are found in β-arrestin-1 and GRK2 protein levels from brain lysates (Supplementary Fig. 2). In addition, MOP coupling to GIRK channels in locus coeruleus and respiratory-related Kölliker-Fuse (KF) neurons is not significantly different between WT and 10S/T-A knock-in mice (Supplementary Fig. 3).

**Lack of acute MOP desensitization.** First, we assessed the rapid desensitization of MOP coupling to GIRK channels in locus coeruleus neurons from horizontal brain sections of mice from all four genotypes. In all experiments, outward currents peak and decline during the 10 min application period of a saturating concentration of the endogenous opioid peptide [Met5]enkephalin (ME) (Fig. 1c). The decline from the peak values varies with genotype. In slices from WT and S375A animals, currents decrease to 50-60% of peak values, whereas the decline is much smaller in slices from 10S/T-A and 11S/T-A animals (Fig. 1c, d). Following washout of ME, effects of 1 µM ME are reduced by ~50% in slices from WT and S375A animals, but remain almost unchanged in 10S/T-A and 11S/T-A animals (Fig. 1c, d) compared to controls. Application of ME (1 µM) at various times following washout of the saturating ME concentration establishes that recovery from the smaller desensitization in slices from 10S/T-A and 11S/T-A animals is rapid, occurring within 5–10 min (Fig. 1c, d). Thus, mutation of S/T sites on the carboxyl-terminus of MOP results in a profound reduction, but not elimination, of two measures of acute desensitization. The small residual desensitization in 10S/T-A and 11S/T-A neurons resembles the heterologous desensitization that has been reported between MOP and the alpha-2-adrenoceptor upon activation of the same potassium conductance.15. The observation that 11S/T-A and 10S/T-A mice have very similar phenotypes indicates that phosphorylation of T394 is not involved in rapid MOP desensitization.
dominant phenotype of the mutant receptor (Supplementary Fig. 5). In 10S/T-A and 11S/T-A mice, the maximum possible analgesic effect (30-s cutoff) is reached after administration of 0.2 mg/kg fentanyl (Fig. 2a). In contrast, in WT mice, administration of 0.3 mg/kg fentanyl is required to achieve the maximum possible effect (Fig. 2a). The 50% effective dose (ED$_{50}$) values determined in the hot-plate test strongly depend on the temperature, which was set at 56°C, and cutoff for analgesia testing, which was set at 30 s. Under these conditions, the ED$_{50}$ value for fentanyl is twofold lower in 10S/T-A and 11S/T-A mice than in WT mice, indicating that the analgesic potency of fentanyl is increased when carboxyl-terminal phosphorylation and β-arrestin recruitment are abolished (Table 1, Fig. 2a). The duration of action of fentanyl is also prolonged (Fig. 2c, d).
**Fig. 2** Enhanced opioid-mediated analgesia in phosphorylation-deficient MOP knock-in mice. **a–d** Acute antinociceptive response measured in the mouse hot-plate test 15 min (fentanyl) or 30 min (morphine) after drug administration. Nociceptive latencies were defined by paw withdrawal and are reported as percent maximum possible effect (% MPE) with a 30-s cutoff. **a, b** Cumulative dose-response curves in S375A, 10S/T-A and 11S/T-A compared to those in WT mice (n = 9–12) after a, fentanyl (F_{genotype,3, 44} = 62.32, P < 0.0001; F_{dose,4, 176} = 1490, P < 0.0001) or b, morphine (F_{genotype,3, 39} = 95.24, P < 0.0001; F_{dose,4, 176} = 1363, P < 0.0001). **c, d** Analgesic time course of acutely administered fentanyl **c** (F_{genotype,3, 21} = 71.28, P < 0.0001; F_{time,6, 126} = 463.9, P < 0.0001) or morphine **d** (F_{genotype,3, 21} = 66.14, P < 0.0001; F_{time,6, 126} = 336.1, P < 0.0001) was repeated after fentanyl and morphine administration, respectively, for the indicated times (n = 6–7). Data are the means ± s.e.m. * indicates statistically significant differences compared to WT; two-way ANOVA with Bonferroni post hoc test.

**Table 1** Analgesic potency before and after chronic treatment

| Fentanyl (mg kg\(^{-1}\)) | Day – 1 | Day 7 | Fold shift | Morphine (mg kg\(^{-1}\)) | Day – 1 | Day 7 | Fold shift |
|---------------------------|--------|-------|------------|---------------------------|--------|-------|------------|
| WT                        | 0.21 ± 0.005 | 2.35 ± 0.234\(^d\) | 11.11 ± 1.018 | 26.64 ± 1.498 | 65.11 ± 3.587\(^d\) | 2.49 ± 0.126 |
| S375A                     | 0.15 ± 0.008\(^*\) | 0.22 ± 0.009 | 1.53 ± 0.080\(^d\) | 25.09 ± 1.477 | 67.27 ± 5.690\(^d\) | 2.75 ± 0.257 |
| 10S/T-A                   | 0.12 ± 0.004\(^*\) | 0.16 ± 0.009 | 1.35 ± 0.066\(^d\) | 12.72 ± 0.222\(^*\) | 22.01 ± 1.093\(^d\) | 1.74 ± 0.094\(^#\) |
| 11S/T-A                   | 0.12 ± 0.006\(^*\) | 0.21 ± 0.009 | 1.80 ± 0.121\(^d\) | 11.76 ± 0.277\(^*\) | 22.83 ± 1.243\(^d\) | 1.95 ± 0.108\(^#\) |

Summary of pED\(_{50}\) values (mg kg\(^{-1}\)) for hot-plate cumulative dose-response curves before (day –1) and after (day 7) chronic treatment with osmotic pumps delivering fentanyl (2 mg/kg/day) or morphine (17 mg/kg/day) (n = 9–12). Data are the means ± s.e.m.

\(^*\) indicates statistically significant differences in the comparison of pED\(_{50}\) values on day –1 to those values in WT (for fentanyl: F\(_{6, 44}\) = 56.47, P < 0.0001; for morphine: F\(_{6, 37}\) = 52.76, P < 0.0001)

\(^d\) indicates statistically significant differences in the comparison of pED\(_{50}\) values between days –1 and 7 (fentanyl: F\(_{6, 44}\) = 86.14, P < 0.0001; morphine: F\(_{6, 37}\) = 75.56, P < 0.0001)

\(^#\) indicates statistically significant differences in the comparison of the fold shift to that in WT (fentanyl: F\(_{6, 44}\) = 72.97, P < 0.0001; morphine: F\(_{6, 37}\) = 9.103, P = 0.0001). One-way ANOVA with Bonferroni post hoc test.

Supplementary Fig. 6). Furthermore 10S/T-A and 11S/T-A mice also display significantly greater and prolonged duration of antinociceptive responses to acute administration of morphine compared to WT mice (Table 1, Fig. 2b, d). Interestingly, S375A mice display greater antinociception than WT after fentanyl (but only during the first 30 min) but not after morphine (Table 1, Fig. 2). Significantly enhanced morphine analgesia in S375A mice was only observed in time course studies at 60 min (Fig. 2d). Overall, these observations suggest that in the absence of rapid MOP desensitization, 10S/T-A and 11S/T-A receptors continue to signal for extended periods leading to increased sensitivity to both fentanyl and morphine. Thus, carboxyl-terminal multisite phosphorylation is a key determinant of MOP responsiveness in vivo.
Exacerbated opioid side effects. Respiratory depression and constipation are serious dose-limiting side effects of classical opioids. Previous genetic studies with β-arrestin-2 knockout mice and suggestions from some studies of biased agonists indicate that MOP signalling through the β-arrestin pathway may contribute to these potentially lethal side effects, whereas MOP signalling via G proteins is thought to confer analgesia. However, there is no direct evidence that the severity of these adverse effects involves recruitment of the β-arrestin pathway. Because recruitment of β-arrestin proteins and MOP internalization are reduced in S375A MOP in vitro and abolished in 10S/T-A and 11S/T-A mutants, we anticipated that total phosphorylation-deficient mice would experience significantly reduced opioid side effects. To compare the side effects across genotypes, we administered nearly equianalgesic doses of fentanyl or morphine and monitored respiration frequency, defecation and locomotor activity over time. Under these conditions, both fentanyl and morphine induce profound respiratory depression, constipation and hyperlocomotion in all genotypes (Fig. 3, Supplementary Fig. 7a). The effects observed are almost indistinguishable between genotypes (Fig. 3, Supplementary Fig. 7a, 8). We then determined respiratory depression and constipation over a broad dose range of fentanyl or morphine and calculated ED₅₀ values (Supplementary Fig. 7b, c, Supplementary Table 1). Notably, we observed that 10S/T-A and 11S/T-A mice exhibit significantly greater respiratory depression than WT mice. When we plotted the ED₅₀ values for morphine analgesia in WT, S375A, 10S/T-A and 11S/T-A mice against their respective ED₅₀ values for respiratory depression and constipation we found highly significant correlations (Fig. 4, Supplementary Table 1), suggesting that both opioid effects cannot be uncoupled. KF neurons are known to contribute to opioid-induced respiratory depression. However, MOP-mediated GIRK currents in KF neurons from 10S/T-A mice are similar to those in WT mice (Supplementary Fig. 3). Taken together, our findings suggest that the maintained G-protein signalling observed in total phosphorylation-deficient MOP knock-in mice leads to enhanced analgesia and to a proportional increase in opioid side effects that does not support a role for β-arrestin signalling in severity of respiratory depression or constipation. Conditioned place preference was also assessed after fentanyl and morphine treatment. Both WT and 11S/T-A mice clearly developed conditioned place preference (Supplementary Fig. 8a, b). However, there was no significant difference between genotypes (Supplementary Fig. 8c, d).

Loss-of-analgesic tolerance. In the clinical setting, analgesic tolerance usually develops with continued use of moderate levels of a drug. Given that the duration of action of fentanyl or morphine is limited to 3 or 6 h, respectively, in mice (Fig. 2c, d), chronic-treatment regimens with once- or twice-daily injections result in extended drug-free intervals. In the absence of the drug, chronic-treatment regimens with once- or twice-daily injections of fentanyl is limited to 3 or 6 h, respectively, in mice (Fig. 2c, d). However, the rightward potency shift observed in 10S/T-A and 11S/T-A mice is significantly less pronounced than that observed in WT and S375A mice (Table 1, Fig. 5c). There are no significant changes in MOP density levels across genotypes following chronic fentanyl or morphine treatment (Supplementary Fig. 1). These results demonstrate that tolerance to both fentanyl and morphine is profoundly blunted in 10S/T-A and 11S/T-A mice, although a modest level of tolerance to morphine remains in total phosphorylation-deficient MOP knock-in mice.

Retained signs of physical dependence. Prolonged exposure to opioids leads to the development of physical dependence on the drug. As tolerance is strongly diminished in phosphorylation-deficient mice, we investigated whether they would still become dependent by assessing withdrawal responses after administration of the opioid antagonist naltrexone on day 8 after pump implantation. Notably, although these mouse lines differ markedly in their development of tolerance, they still display typical signs of withdrawal including jumping, wet-dog shakes and grooming. Quantitative analysis of these behaviours using a global withdrawal score did not reveal significant differences between the genotypes (Fig. 5b, c, Supplementary Fig. 9). However, S375A, 10S/T-A and 11S/T-A mice display significantly greater withdrawal-associated weight loss, which is not included in the calculation of the global withdrawal score (Fig. 5b, c). Although total phosphorylation-deficient mice do not become tolerant to opioids, they clearly become dependent on them.

Discussion

By constructing mice exclusively expressing MOP receptors with carboxyl-terminal regions that progressively evade phosphorylation by GRKs and other serine/threonine kinases (10S/T-A and 11S/T-A), we have established here that carboxyl-terminal multisite phosphorylation is the proximal molecular event driving MOP desensitization and the development of long-term opioid analgesic tolerance, but not side effects or withdrawal. Although previous studies in transfected HEK293 and AtT20 cells have implicated phosphorylation by GRK2 and GRK3 and binding of the scaffolding proteins β-arrestin-1 and β-arrestin-2 in MOP desensitization, until now the contribution of carboxyl-terminal S/T phosphorylation to the physiological regulation of MOP has not been directly tested in vivo. When the ED₅₀ values of morphine analgesia in S375A, 10S/T-A and 11S/T-A mice were significantly higher than those in WT mice, we found that S375A, 10S/T-A and 11S/T-A mice displayed significantly greater withdrawal-associated weight loss, which is not included in the calculation of the global withdrawal score (Fig. 5b, c). Although total phosphorylation-deficient mice do not become tolerant to opioids, they clearly become dependent on them.

MOP desensitization in LC neurons by ME (which stimulates MOP phosphorylation and β-arrestin-2 recruitment with a similarly high efficacy to fentanyl) is not significantly affected by the S375A mutation, which had an intermediate effect on enhancing the magnitude and duration of analgesia induced by fentanyl and almost no effect on the response to morphine in vivo. It is widely established that the S375A mutation reduces overall phosphorylation of proximal residues by GRKs and strongly impairs β-arrestin-2 recruitment, without affecting G-protein signalling. The increase in potency of fentanyl, but not morphine in S375A suggests that GRK/β-arrestin mechanisms contribute to limiting the acute effects of these opioids in vivo. More importantly, the mutation had no differential effects on the potency of either fentanyl or morphine to induce respiratory depression or constipation, strongly suggesting that opioid side effects are mediated by a mechanism independent of β-arrestin recruitment to MOP and, therefore, pharmacological or other approaches aimed at reducing β-arrestin recruitment to MOP might not improve the safety profile.
of opioids. Complete or near complete removal of carboxy-terminal phosphorylation sites (10S/T-A and 11S/T-A, respectively) reinforced this view, with both mutations greatly attenuating desensitization in neurons and further enhancing fentanyl and morphine potency and duration of action but without any ameliorations of the side effects. The hypothesis that β-arrestin signalling may be responsible and required for side effects such as respiratory depression is also refuted by our finding that physiological actions of ME in KF neurons were unaffected or even enhanced in the nearly complete phosphorylation-deficient 10S/T-A mice. The lack of change in MOP density across genotypes in naive and chronic fentanyl or morphine-treated mice indicates that any phenotypic alterations observed were not due to alterations in opioid receptor levels.

The novel pharmacological concept of functional selectivity or biased agonism is based on the observation that structurally
distinct G-protein-coupled receptor (GPCR) ligands can stabilize alternative receptor conformations upon binding, with each displaying a unique pattern of activation of intracellular signalling cascades. Biased agonism has been proposed as a means to separate desirable from adverse drug responses downstream of a GPCR target. Genetic studies with global β-arrestin-2 knockout mice indicate that opioid side effects such as respiratory depression and constipation primarily may engage the β-arrestin-signalling pathway, whereas analgesia is thought to primarily engage the G-protein-signalling pathway downstream of MOP. By generating phosphorylation-deficient knock-in mice, we have created a model that allows precise genetic dissection of signalling bias at the MOP level. As 10S/T-A and 11S/T-A mutants signal via G proteins for prolonged periods without apparent desensitization but at the same time fail to recruit β-arrestin proteins, these mutants can be viewed as completely G-protein-biased MOP receptors — contrary to prediction — do not show improved side effect profiles. This finding seems to be at odds with some observations in β-arrestin-2 knockout mice, but compensatory recruitment of β-arrestin-1 might explain the differences. We also suggest that the modest improvement in safety profile of some strongly G-protein-biased agonists may be attributable to pharmacological properties other than the loss of β-arrestin signalling. Identifying such properties may provide valuable clues for the development of safer opioids.

The profound long-term tolerance induced by fentanyl was nearly abolished in the phosphorylation-deficient mutants, but although morphine tolerance was significantly diminished, it was not completely eliminated even in mice with MOP that lacked all possible S/T phosphorylation sites from the carboxyl-terminus. This suggests that additional mechanisms may contribute specifically to the morphine-dependent regulation of MOP. Such additional regulatory elements may include GRK5, β-arrestin-2, and protein kinase C (PKC) or c-Jun N-terminal kinase 2 (JNK2). Previous studies have shown that morphine-activated MOP receptors are predominantly phosphorylated by GRK5 and preferentially recruit β-arrestin-2 but not β-arrestin-1. While genetic inactivation of GRK5 does not affect morphine tolerance, global knockout of β-arrestin-2 leads to a selective attenuation of antinociceptive tolerance to morphine. However, in as far as phosphorylation-deficient MOP fails to efficiently recruit β-arrestin proteins, β-arrestin-2 is unlikely to contribute to the residual morphine tolerance observed in 10S/T-A and 11S/T-A mice. PKC activity seems to be specifically required for morphine-dependent desensitization of MOP in LC neurons. In AtT20 cells, morphine-induced desensitization was reduced by PKC inhibition in WT MOP receptors and abolished in the 11S/T-A mutant. Thus, morphine may induce analgesic tolerance in 10S/T-A and 11S/T-A mice by a PKC activity-dependent mechanism that may involve phosphorylation of S/T residues in cytoplasmic loops of MOP or phosphorylation of other signalling molecules. Superactivation of the cAMP-signalling pathway in response to chronic opioid treatment is often viewed as a cellular hallmark of opioid withdrawal. Our observation that 10S/T-A and 11S/T-A mice do not become tolerant but experience all behavioural signs of withdrawal, which are mostly unchanged except for enhanced weight loss, indicates that phosphorylation-deficient...
mice develop the same biochemical adaptations as WT mice in the absence of tolerance. Again this observation suggests that G-protein-biased opioids may not reduce the development of opioid dependence or withdrawal after long-term treatment. The adaptive responses associated with cAMP superactivation, most notably increased expression of adenylyl cyclases, are also thought to oppose chronic opioid action, which may in turn be a source of diminished pain control. Moreover, the RAVE (relative activity versus endocytosis) hypothesis predicts that aberrantly prolonged MOP-signalling would facilitate the development of tolerance. Our findings of loss of tolerance to fentanyl and morphine but retention or enhancement of withdrawal behaviour in the phosphorylation-deficient mutants do not support the view that this type of opponent process greatly contributes to analgesic tolerance. Thus, tolerance and dependence are two dissociable phenomena and the total phosphorylation-deficient mice we have developed represent a powerful means of dissecting the molecular pathways leading to physical dependence and addiction in a non-tolerant animal model (Fig. 6).

Finally, we indeed observed functional selectivity in these animals, in that different opioid agonists can engage different mechanisms to induce tolerance. Several recent studies have discovered novel-biased opioids with reduced side effects in animal models compared to classical opioids. Signalling bias at opioid receptors can be envisioned at the level of G_i versus G_o or other G-proteins, GRK2/3 versus GRK5 or PKC, and β-arrestin-1 versus β-arrestin-2 proteins. Thus, our results indicate that the biased agonism hypothesis needs to be extended to all potential levels of bias, while simultaneously interrogating other pharmacological properties of improved opioids. Finally, our results suggest that novel chemotypes require detailed evaluation of beneficial signalling bias to allow for a precise prediction of their therapeutic window in our search for safer opioids.
Phosphorylation-deficient, G-protein-biased MOP receptors enhance analgesia, but worsen side effects. Carboxyl-terminal multisite phosphorylation is the key step that drives acute MOP receptor desensitization and long-term tolerance. In the absence of MOP phosphorylation, arrestin recruitment is increasingly impaired yet phosphorylation-deficient MOP receptors can mediate opioid side effects such as respiratory depression, constipation and dependence.

Methods

Animals. Knock-in mice expressing the 105S/T-A (Oprtm1tm2.1shlz, MGI:6176688) and 11S/T-A (Oprtm1tm3.1shlz, MGI:6176763) mutant MOP gene were generated by Genoway (Lyon, FRA) and Ozone (Bentley, AUS), respectively. Mice were genotyped by PCR analysis of genomic tail DNA using the following primers: 105S/T-A: 5′-TTCATCTGTCAAGGCTTTGTCCTCCTTCGGC-3′ and 5′-TGGAGATATCTTTGACATGATGATGATGATGGAC-3′; 11S/T-A: 5′-TAAATGATGATGATGATGATGATGATGATGGAC-3′, 5′-TGGAGATATCTTTGACATGATGATGATGATGGAC-3′, 5′-TGGAGATATCTTTGACATGATGATGATGATGGAC-3′, and 5′-TGGAGATATCTTTGACATGATGATGATGATGGAC-3′. Knock-in mice expressing the S375A MOP mutant (Oprtm1tm1shlz, MGI:5000465) were generated and characterized as previously described. All MOP mutants were backcrossed to WT control JAX™ C57BL/6J mice from Charles River Laboratories (DE), which were also used for the breeding of mutant strains and as controls in all experiments. WT littermates from all three MOP mutants did not differ significantly in any of the behavioural tests. For electrophysiology studies, male and female WT C57BL/6J mice (Jackson Laboratory, Sacramento, CA) were used together with all mutant strains. Animals were housed 2–5 per cage under a 12-h light–dark cycle with ad libitum access to food and water. In all behavioural experiments, we used male mice aged 8–16 weeks and weighing 25–30 g. To increase statistical power, we used 6–16 mice per genotype for each experimental group. Studies were performed in parallel such that age-matched mice received the same drug treatment at the same time. To avoid daytime effects, studies were carried out in small cohorts of mice (n = 6) at a time. The animal experiments conducted at Jena University Hospital were performed in accordance with the Thuringian state authorities, compiled with the European Commission regulations for the care and use of laboratory animals, were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The animal experiments conducted at University of Oregon were approved by Oregon Health and Science Institutional Animal Care and Use Committee. The animal experiments conducted at University of Sydney were performed under the guidelines of the Australian code of practice for the care and use of animals for scientific purposes (National Health and Medical Research Council, Australia, 7th Edition) and were approved by the University of Sydney Animal Ethics Committee. Our study is reported in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.

Drugs and routes of administration. All drug doses were calculated according to the active component of the salt. All drugs [morphine sulphate (3.75–120 mg kg⁻¹; Hamelin Inc., Hameln, Germany), fentanyl citrate (0.2–4 mg kg⁻¹; Rotemedica, Trittau, Germany), and naloxone hydrochloride (2 mg kg⁻¹; Ratiopharm, Ulm, Germany), used to precipitate withdrawal] were freshly prepared prior to use and were injected subcutaneously in lightly restrained, unanaesthetized mice at a volume of 10 µL g⁻¹ body weight. For chronic infusion with Alzet osmotic mini-pumps (1007D), fentanyl citrate salt (2 mg kg⁻¹ day⁻¹) and morphine sulphate salt pentahydrate (17 mg kg⁻¹ day⁻¹) were obtained from Sigma-Aldrich (St. Louis, MO). Drugs were diluted in phosphate-buffered saline for acute injections or dissolved in sterile water and then diluted in phosphate-buffered saline for osmotic pump delivery. For electrophysiology studies, MK-801 was obtained from HelloBio (Princeton, NJ). [Met⁵]enkephalin (ME), bestatin and thiorphan were from Sigma-Aldrich.

Autoradiographic binding assay. Following decapitation, intact brains were removed, snap frozen at −20 °C in isopentane and stored at −80 °C. Adjacent sections from WT, S375A, 105S/T-A and 115S/T-A brains were cut at 300-µm intervals from fore- to hindbrain in a cryostat (Leica CM1900, UK) at −21 °C for determination of total and non-specific binding. Sections were stored at −20 °C for MOP radioligand binding as described previously. Sections were pre-incubated for 30 min in 50 mM Tris-HCl, 0.9% w/v NaCl, pH 7.4, at room temperature. Slides were incubated in 50 mM Tris-HCl buffer, pH 7.4, at room temperature in the presence of 4 nM [³H]DAMGO for 60 min. Non-specific binding was determined in adjacent sections in the presence of 1 µM naltrexone. Incubation was terminated by rapid rinses (3 × 5 min) in ice-cold 50 mM Tris-HCl buffer, pH 7.4, at room temperature. Slides were then rapidly cool-air-dried for 2 h and dried for up to 7 days over anhydrous calcium sulphate (BDH Chemicals, Poole, UK). Adjacent total binding and non-specific sections were opposed to Kodak BioMax MR-1 film alongside [³H]microscale standards for a period of 10 weeks for the detection of opioid receptors. Films were analysed by video-based densitometry using an MCID image analyser ( Imaging Research, Canada) as previously described. For each region quantified, measures were taken from both left and right hemispheres; therefore, receptor binding represents a duplicate determination for each brain region, and n values refer to the number of animals analysed. The following structures were analysed by sampling 5–20 times with a box tool: cortex (8 × 8 mm), and cingulate cortex (8 × 8 mm). All other regions were analysed by freehand drawing. Brain structures were identified by reference to the mouse brain atlas. Specific binding in each brain region from WT, S375A, 105S/T-A and 115S/T-A brains was compared by two-way ANOVA with Bonferroni post hoc tests.

Brain slice preparation for electrophysiology. Mice were anaesthetized using isoflurane (Patterson Veterinary, Devens, MA) and killed by decapitation, and brains were extracted and sectioned into 250-µm-thick horizontal slices containing the locus coeruleus (Leica VT1000S, Vashaw Scientific, Norcross, GA). Slices were cut at 32 °C in oxygenated (95% O₂/5% CO₂) artificial cerebrospinal fluid consisting of NaCl (126 mM), KCl (2.5 mM), NaH₂PO₄ (1.2 mM), MgCl₂ (1.2 mM), NaHCO₃ (21.4 mM) and D-glucose (11 mM). The cutting solution contained MK801 (0.01 mM); [S5,10R] (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5,10-imine; (−)-55 mV and currents were recorded continuously (200/s) throughout each experiment. After establishing whole-cell recording mode, neurons were allowed to stabilize for 5–10 min prior to drug application (1 µM in the presence of 10 µM bestatin and 1 µM thiorphan to inhibit peptidase activity). Outward currents induced by ME (1 µM) ranged from 30 to 70 pA, rose to steady state within 2 min and decayed to control levels within 5 min. Following the test application of ME (1 µM), a saturating concentration of ME (30 µM) was applied for 10 min and then washed out. The decline from the peak was calculated by measuring the current at the end of a 10 min application of ME (30 µM) divided by peak current-induced shortly after (within 2 min) the application of ME (30 µM). The post/pre-measure is the amplitude of the current induced by ME (1 µM) 5 min following the washout of ME 30 µM divided by the
initial current induced by ME (1 µM). The recovery from the desensitization induced by ME (30 µM, 10 min) was measured at 5, 10 and 20 min following the washout of the high concentration of ME. The amplitude of the current induced by ME (1 µM) was measured at each time point and normalized to the amplitude of the current induced by ME prior to the application of the high concentration of ME. Significant differences between groups were determined by unpaired two-tailed t-tests or by two-way ANOVA with Bonferroni or Dunnnett’s post hoc tests. Values are given as the means ± s.e.m. and n = number of cells.

**Osmotic pump implantation.** A single 1007D Alzet osmotic minipump (Charles River Laboratories, DE) was subcutaneously implanted on the left limb of each mouse under light isoflurane anaesthesia and meloxicam analgesia 7 days before behavioural experiments. A small incision was made in the skin on the mouse’s left flank with a scalpel, a small pocket was formed just beneath the skin, and the minipump was inserted. The incision was closed using 7-mm wound clips (Charles River Laboratories).

**Behavioural studies.** For consistency, one experimenter and a dedicated assistant performed all in vivo drug administrations and behavioural testing. All testing was conducted between 7 a.m. and 4 p.m. in an isolated, temperature- and light-controlled room. Mice were acclimated for at least 2 weeks before testing. Only the experimenter and assistant had free access to the room and entered the room 30 min before commencement of testing to eliminate potential olfactory-induced changes in nociception. Animals were assigned to groups randomly before testing. Mice were excluded from the study if they displayed any bodily injuries from aggression with cage mates. The experimenter was blinded to treatment and/or genotype throughout the course of behavioural testing. All drugs were given to the experimenter in coded vials and decoded after completion of the experiment.

Hot-plate test. Opiate effects on pain withdrawal latencies were assessed as the time to response (licking or flicking fore or hind paw(s)) after placement on a hot-plate maintained at 56 °C (Ugo Basile SRL, IT)11,14. To avoid tissue damage, we used a 30-s cutoff. The hot-plate test was carried out 15 min (fentanyl) or 30 min (morphine) after drug administration and expressed as percent maximum possible effect (% MPE). Baseline data were collected 15 min before commencement of testing to eliminate potential olfactory-induced changes in nociception. Analgesia thresholds were determined at 5 min intervals with 0.02, 0.03, 0.05, 0.1 and 0.1 mg kg$^{-1}$ fentanyl or 0.1 mg kg$^{-1}$ morphine to yield final cumulative doses of 0.02, 0.05, 0.1, 0.2 and 0.3 mg kg$^{-1}$ fentanyl, and latencies were measured 15 min after drug administration, immediately followed by additional drug except for the last dose. For morphine dose-responses, mice were injected at 30 min intervals with 0.2, 0.5, 1, 2 and 3 mg kg$^{-1}$ morphine resulting in final cumulative doses of 0.35, 0.7, 2.25, and 5.25 mg kg$^{-1}$ morphine. Hot-plate latencies were always measured 30 min after morphine administration, immediately followed by the next dose. Dose-response curves generated using repeated cumulative dosing regimen are shown in Fig. 2a, b. These curves were used to calculate % MPE, which was calculated as shown in each behavioural method section. The authors declare that all data supporting the findings of this study are available within the paper and its supplementary information files. The source data underlying all figures are available as a Nature Data file. The data that support the findings of this study are available from the authors upon reasonable request.

Received: 24 May 2018 Accepted: 18 December 2018
Published online: 21 January 2019

**References**

1. Williams, J. T. et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223–254 (2013).
2. Koob, G. F., Sanna, P. P. & Bloom, F. E. Neuroscience of addiction. Neuron 21, 467–476 (1998).
3. Nestler, E. J. & Aghajanian, G. K. Molecular and cellular basis of addiction. Science 278, 58–65 (1997).
4. Chen, Y. J. et al. Identification of phosphorylation sites in the COOH-terminal tail of the mu-opioid receptor. J. Neurochem. 124, 189–199 (2013).
5. Doll, C. et al. Agonist-selective patterns of micro-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br. J. Pharmacol. 164, 298–307 (2011).
6. Just, S. et al. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol. Pharmacol. 83, 633–639 (2013).
7. Lau, E. K. et al. Quantitative encoding of the effect of a partial agonist on individual opioid receptors by multisite phosphorylation and threshold detection. Sci. Signal. 4, ra2 (2011).
8. Schulz, S. et al. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J. 23, 3282–3289 (2004).

---

**Data availability**

The authors declare that all data supporting the findings of this study are available within the paper and its supplementary information files. The source data underlying all figures are available as a Nature Data file. The data that support the findings of this study are available from the authors upon reasonable request.
9. Yousaf, A. et al. Role of phosphorylation sites in desensitization of micro-opioid receptor. *Mol. Pharmacol.* 88, 825–835 (2015).

10. Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. & Caron, M. G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. *Nature* 408, 720–723 (2000).

11. Bohn, L. M. & Caron, M. G. Role of protein kinase C and mu-opioid receptor (MOPr) phosphorylation and desensitization in tolerance to morphine in rat locus coeruleus neurons. *J. Neurosci.* 31, 1195–1200 (2011).

12. Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. & Caron, M. G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. *Nature* 408, 720–723 (2000).

13. Bohn, L. M. et al. Enhanced mu-opioid receptor analgesia in mice lacking beta-arrestin-2. *Science* 286, 2495–2498 (1999).

14. DeWiere, S. M. & et al. A G protein-biased ligand at the mu-opioid receptor is potentially analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. *J. Pharmacol. Exp. Ther.* 344, 708–717 (2013).

15. Manglik, A. et al. Structure-based discovery of opioid analogues with reduced desensitization of alpha(2A)-adrenoceptor function in locus cereuleus neurons. *Mol. Pharmacol.* 82, 473–480 (2012).

16. Bohn, L. M., Gainetdinov, R. R., Lin, F. T., Lefkowitz, R. J. & Caron, M. G. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. *Nature* 408, 720–723 (2000).

17. Terman, G. W. et al. G-protein receptor kinase 3 (GRK3) in Jun N-terminal kinase activation disrupts opioid receptor signaling. *Acad. Sci. USA* 106, 7200–7205 (2009).

18. Avidor-Reiss, T. et al. Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. *J. Biol. Chem.* 270, 29752–29758 (1995).

19. Birdsong, W. T., Arttamangkul, S., Bunzow, J. R. & Williams, J. T. Agonist binding and desensitization of the mu-opioid receptor is modulated by phosphorylation of the C-terminal tail domain. *Mol. Pharmacol.* 88, 816–824 (2015).

20. Gluck, L. et al. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 3. *Biol. Psychiatry* 76, 767–774 (2014).

21. Doll, C. et al. Deciphering micro-opioid receptor phosphorylation and desphosphorylation in HEK293 cells. *Br. J. Pharmacol.* 167, 1259–1270 (2012).

22. Misseri, R. et al. Multi-site phosphorylation is required for sustained interaction with GRKs and arrestins in mediating rapid mu-opioid receptor desensitization. *Sci. Signal.* eaas9609. https://doi.org/10.1126/scisignal.aas9609 (2018).

23. Grecksch, G. et al. Algalicase tolerance to high-effacy agonists but not to morphine is diminished in phosphorylation-deficient S337A mu-opioid receptor knock-in mice. *J. Neurosci.* 31, 13890–13896 (2011).

24. Rusnak, A. et al. Role of protein kinase C and mu-opioid receptor (MOPr) phosphorylation and desensitization in overcoming cross tolerance to morphine in rat locus coeruleus neurons. *J. Pharmacol. Exp. Ther.* 320, 1–3 (2007).

25. Schmid, C. L. et al. Bias factor and therapeutic window correlate to predict safer opioid analogues. *Cell* 171, 1165–1175 e1113 (2017).

26. Levitt, E. S., Hunnicutt, B. J., Knopp, S. J., Williams, J. T. & Bissonnette, J. M. A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome. *J. Appl. Physiol. Respir. Environ. Exerc. Physiol.* 55, 250–253 (1983).

27. Illing, S., Mann, A. & Schulz, S. Heterologous regulation of agonist-independent mu-opioid receptor phosphorylation by protein kinase C. *Br. J. Pharmacol.* 171, 1330–1340 (2014).

28. Bohn, L. M. et al. Enhanced mu-opioid receptor analgesia in mice lacking beta-arrestin-2. *Science* 286, 2495–2498 (1999).

29. Slowik, R. et al. Enhanced morphine analgesia in mice lacking beta-arrestin-2. *Science* 286, 2495–2498 (1999).

30. Prikic, I. et al. Pontine mu-opioid receptors mediate bradypnea caused by intravenous remifentanil infusions at clinically relevant concentrations in dogs. *J. Neurophysiol.* 108, 2430–2441 (2012).

31. Bohn, L. M. & Bohn, L. M. The role of beta-arrestin-2 in the severity of antinoceptive tolerance and physical dependence induced by different opioid pain therapeutics. *Neuropharmacology* 60, 58–65 (2011).

32. Maldonado, R., Negus, S. & Koo, G. F. Precipitation of morphine withdrawal syndrome in rats by administration of mu- and delta- and kappa-selective opioid antagonists. *Neuropharmacology* 31, 1231–1241 (1992).

33. Rankovic, Z., Brust, T. F. & Bohn, L. M. Biased agonism: an emerging paradigm in GPCR drug discovery. *Biorg. Med. Chem. Lett.* 26, 241–250 (2016).

34. Kuhar, J. R. et al. Mu opioid receptor stimulation activates c-Jun N-terminal kinase 2 by distinct arrestin-dependent and independent mechanisms. *Cell Signal.* 27, 1799–1806 (2015).

35. Melief, E. I., Miyatake, M., Bruchas, M. R. & Chavkin, C. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. *Proc. Natl Acad. Sci. USA* 107, 11608–11613 (2010).

36. Chu, J., Zheng, H., Zhang, Y., Loh, H. H. & Law, P. Y. Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization. *Cell Signal.* 22, 684–696 (2010).

37. Avidor-Reiss, E. S., Hunnicutt, B. J., Knopp, S. J., Williams, J. T. & Bissonnette, J. M. A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome. *J. Appl. Physiol.* 115, 1626–1633 (2013).

Acknowledgements
We thank Helga Bechmann, Elke Miess, Pooja Dasgupta, Sebastian Fritzwaner and Heike Stadler for excellent technical assistance, Ralf Stumon for discussion and Rainer Reinheckel for critical reading of the manuscript. This work was supported by the Deutsche Forschungsgemeinschaft grants SFB/TR166-TCP5 and SCHU924/10-3 to S.S., NIH DA08163 to J.T.W., National Health and Medical Research Council of Australia (APP1072113 and 1045964) to M.J.C., Horizon 2020 EU funding SmokeFreeBrain 681120 to A.B. and NIH DA038069 to E.S.L.

Author contributions
S.S. initiated the project and designed all behavioural pharmacology experiments with A. K.AK. performed all in vivo studies. F.S. performed mouse plethysmography, accumulated faecal bolii studies and CPP. S.S., M.I.C. and J.T.W. performed electrophysiology on the locus coeruleus and E.S.L. and J.T.B. performed the experiments on the Kölliker-Fuse nuclei. A.B. performed the autoradiographic binding assay. The manuscript was written by S.S., A.K. and M.J.C. with editing and suggestions from A.B.

Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-08162-1.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/.

Journal peer review information: Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article that are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material, are not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019